Baricitinib

Evidence Level: L5

Predicted Indications: 2

Baricitinib

Pharmacist Assessment Report

Baricitinib: From Rheumatoid Arthritis to Colobomatous Microphthalmia-Rhizomelic Dysplasia Syndrome

One-Sentence Summary

Baricitinib was originally used to treat rheumatoid arthritis. The TxGNN model predicts it may be effective for colobomatous microphthalmia-rhizomelic dysplasia syndrome, but 0 clinical trials and 0 publications currently support this prediction, so it rests on the model alone.

Quick Overview

Item	Content
Original Indication	Rheumatoid arthritis
Predicted New Indication	Colobomatous microphthalmia-rhizomelic dysplasia syndrome
TxGNN Prediction Score	0.9994
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 2 of 2)
Number of DINs	2 (marketed: 2)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the data compiled for this report. Baricitinib is generally known as a JAK1/JAK2 inhibitor, and its efficacy in rheumatoid arthritis, an immune-mediated inflammatory disease, is established.

The predicted condition is a rare congenital malformation syndrome involving eye defects (coloboma and microphthalmia) and skeletal shortening (rhizomelic dysplasia). Nothing in the compiled data connects JAK-STAT inhibition to the biology of this condition. Because it is a developmental disorder, an anti-inflammatory mechanism seems biologically implausible without further evidence.

The very high TxGNN score (0.9994) is a computational prediction only. It is not backed by trials or literature, so it should be treated as a likely false positive until a plausible biological pathway is shown.

Second predicted indication: The model also ranks brachydactyly-syndactyly syndrome (score 0.9994, also Evidence Level L5, Hold). It likewise has no trials or literature, and it is a structural limb malformation with no demonstrated link to JAK inhibition.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02544768	OLUMIANT	Not specified	Not specified
02480018	OLUMIANT	Not specified	Not specified

Safety Considerations

Drug Interactions: The data compiled for this report lists 100 interacting drugs (from DDInter). The entries shown include:

Major: corticosteroids (hydrocortisone, prednisone, prednisolone, dexamethasone, betamethasone, budesonide, triamcinolone including the ophthalmic form), deferiprone, and radiopharmaceuticals/radioimmunotherapy agents (ibritumomab tiuxetan, iobenguane I-131, tositumomab I-131)
Moderate: morphine (including liposomal), opium, acetylsalicylic acid, nitisinone
Minor: zinc salts (acetate, gluconate, sulfate)

Please refer to the package insert for warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction is supported only by a model score, with no clinical trials or literature. There is no plausible mechanistic link between JAK1/JAK2 inhibition and a congenital developmental malformation syndrome. It is most likely a false positive.

To proceed, the following is needed:

Mechanism of action data and a credible biological pathway linking JAK-STAT signalling to this syndrome
Preclinical or case-level evidence in the predicted condition
Health Canada package insert warnings and contraindications, which are needed before any safety screening
Approved indication and dosage form details for the two OLUMIANT DINs
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.